What the Sanofi Pasteur TV commercial - The 16 Vaccine is about.
Sanofi Pasteur addresses the importance of immunization in their TV spot titled 'The 16 Vaccine.' The commercial begins by showing the many things that we love and fear we may miss out on due to illness, such as playing with our children and traveling. However, Sanofi Pasteur argues that with their 16 vaccines, people can be protected against more than a dozen diseases that could rob them of these joys.
The TV spot educates the audience on the key benefits of vaccines. It highlights how vaccines not just protect individual health but the health of the wider community. The company also informs that vaccines are well-researched, tested, and proven to be effective in preventing potentially deadly diseases.
The Sanofi Pasteur TV spot emphasizes the importance of taking care of one's health and not risking the chance of falling ill. By taking advantage of Sanofi Pasteur's vaccine lineup, the audience can open up a world of possibilities that were once unattainable due to fear of disease.
The ad leaves the viewers with a thought-provoking message: "Inspired by imagination, driven by science." This tagline underscores the company's mission to eradicate some of the world's most debilitating diseases by harnessing human creativity and innovation.
In conclusion, Sanofi Pasteur's 'The 16 Vaccine' commercial serves as a reminder to the public that vaccines play a crucial role in keeping us healthy and fostering the possibility for new experiences and opportunities.
Sanofi Pasteur TV commercial - The 16 Vaccine produced for
Sanofi
was first shown on television on May 7, 2019.
Frequently Asked Questions about sanofi pasteur tv spot, 'the 16 vaccine'
Sanofi Pasteur has a wide range of standalone and combination vaccines that protect against multiple diseases in a single injection. Some of our paediatric vaccines are used in over 100 countries worldwide.
VidPrevtyn Beta is a monovalent, recombinant-protein next-generation COVID-19 vaccine developed by Sanofi, modelled on the Beta variant and including GSK's pandemic adjuvant. The same recombinant-protein technology is used in Sanofi's approved seasonal flu vaccines.
Menactra
Menactra is indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. Menactra is approved for use in individuals 9 months through 55 years of age.
Sanofi Pasteur is the vaccines division of the French multinational pharmaceutical company Sanofi. Sanofi Pasteur is the largest company in the world devoted entirely to vaccines.
Commonly Used Sanofi Products
While Sanofi may be best known as the manufacturer of Ambien, the company makes many other commonly used medicines and over-the-counter products.
For over 2 centuries, people have been vaccinated against deadly diseases, ever since the world's first vaccine was devised against smallpox.
The Sanofi vaccine, known as VidPrevtyn Beta, is protein-based and instead contains copies of the SARS-CoV-2 spike protein from the beta variant.
We executed an extensive development program which was based on innovative and proven manufacturing technology to make our protein-based adjuvanted COVID-19 booster vaccine available for use in Europe. Our COVID-19 vaccine was developed in partnership with GSK and US BARDA.
Meningococcal Vaccination
There are 2 types of meningococcal vaccines available in the United States: Meningococcal conjugate or MenACWY vaccines (Menactra®, Menveo®, and MenQuadfi®) Serogroup B meningococcal or MenB vaccines (Bexsero®and Trumenba®)
What Types of Meningococcal Vaccines Are There?
- MenACWY (conjugate) vaccines (Menactra®, Menveo®, and MenQuadfi®)
- MenB (recombinant protein) vaccines (Bexsero® and Trumenba®)
Sanofi Pasteur produces influenza vaccines each year across five international sites: Swiftwater (Pennsylvania, United States), Pearl River (New York, United States), Val-de-Reuil (France), Ocoyoacac (Mexico) and Shenzhen (China). This makes Sanofi Pasteur the largest manufacturer of influenza vaccines in the world.
History. The Sanofi–GSK COVID‑19 vaccine is under development by the French pharmaceutical company Sanofi and the British-American pharmaceutical company GlaxoSmithKline.